Results 101 to 110 of about 32,786 (220)

Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.

Biology of Blood and Marrow Transplantation, 2019
In immunoglobulin light-chain (AL) amyloidosis, the depth of hematologic response to treatment is associated with improved survival and organ responses. We conducted a clinical trial using bortezomib in induction and in conditioning with melphalan before
V. K. Gupta, D. Brauneis, A. Shelton, K. Quillen, S. Sarosiek, J. Sloan, V. Sanchorawala   +6 more
semanticscholar   +1 more source

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine.

Blood, 2018
TO THE EDITOR: Systemic amyloid light-chain amyloidosis (AL) is characterized by deposition of misfolded immunoglobulin light chains within organs. AL with an immunoglobulin M (IgM) monoclonal protein (IgM-AL) accounts for 5% to 7% of AL and exhibits ...
R. Manwani, S. Sachchithanantham, S. Mahmood, Darren Foard, F. Sharpley, T. Rezk, T. Lane, C. Quarta, M. Fontana, H. Lachmann, J. Gillmore, C. Whelan, P. Hawkins, A. Wechalekar   +13 more
semanticscholar   +1 more source

Localized amyloid light-chain amyloidosis and extramedullary plasmacytoma of the mitral valve

, 2013
An unusual case of localized amyloid light-chain (AL) amyloidosis and extramedullary plasmacytoma of the mitral valve is described. The worsening of a mitral regurgitation led to investigations and surgery.
Roumy, A., Kurtin, Paul, von Segesser, L.K., Schäfer, Stephan, von Segesser, Ludwig K., Niclauss, Lars, de Leval, Laurence, Niclauss, L., Ruchat, P., Kurtin, P., Dogan, A., Schaefer, S.C., Ruchat, Patrick, Roumy, Aurélien, Dogan, Ahmet, de Leval, L.   +15 more
core   +1 more source

Natural history and outcome in systemic AA amyloidosis

, 2007
BACKGROUND:Deposition of amyloid fibrils derived from circulating acute-phase reactant serum amyloid A protein (SAA) causes systemic AA amyloidosis, a serious complication of many chronic inflammatory disorders.
Goodman, HJB, Lachmann, HJ, Gillmore, JD, Hawkins, PN, Gilbertson, JA, Gallimore, JR, Sabin, CA   +6 more
core  

Cutaneous light chain amyloidosis and erythema elevatum diutinum as the presenting features of IgA monoclonal gammopathy: a rare case report and comprehensive literature review

Annals of Hematology
Monoclonal gammopathy (MG) associated with dermatological disorders, which is classified as monoclonal gammopathy of clinical significance (MGCS), represents a well-established complication.
Bing Han, Junfeng Zhou, Hesong Liu, Shanshan Li, Hong Wang   +4 more
doaj   +1 more source

Systemic Amyloidosis – Insights by Cardiovascular Magnetic Resonance

, 2015
Systemic amyloidosis is the exemplar infiltrative, extracellular disease. Although it is a multi-organ disorder, cardiac involvement drives prognosis. Survival is worst in the AL amyloidosis subtype. It can affect any age and any race. There is no direct
Banypersad, SM
core  

Cardiac Involvement in Four Patients with Immunoglobulin Light-Chain Systemic Amyloidosis [PDF]

In immunoglobulin light-chain (L) amyloidosis the cause of death is most commonly due to cardiac involvement. Cardiac amyloidosis is frequently diagnosed by postmortem examination. There are many reports of diagnoses of cardiac amyloidosis established by

core   +1 more source

Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis

Haematologica, 2018
Systemic AL amyloidosis (AL) is caused by deposition of misfolded immunoglobulin light chains, leading to potentially catastrophic visceral dysfunction.[1][1] Outcomes are heterogeneous, but cardiac involvement is a key survival predictor.
R. Manwani, Darren Foard, S. Mahmood, S. Sachchithanantham, T. Lane, C. Quarta, T. Youngstein, T. Rezk, H. Lachmann, J. Gillmore, M. Fontana, C. Whelan, P. Hawkins, A. Wechalekar   +13 more
semanticscholar   +1 more source

BCMA CAR T for AL Amyloidosis After Plasmacytic Relapse of Lymphoplasmacytic Lymphoma

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Lambda immunoglobulin light chain (AL) amyloidosis associated with non‐IgM lymphoplasmacytic lymphoma (LPL) is rare and often refractory to conventional therapies. Treatment options for relapsed disease remain limited. Methods Here we describe the case of a patient with a history of LPL‐associated AL amyloidosis who had previously
Nadia Al Haddad, Eugene Brailovski, Jacqueline Dela‐Pena, Melinda Cook, Michael Rosenzweig, Heather Jolie Landau   +5 more
wiley   +1 more source

Pulmonary light chain deposition disease: Case series and review of the literature

Radiology Case Reports
Pulmonary light chain deposition disease is a rare entity characterized by immunoglobulin deposition within the lung parenchyma with pathologic features distinct from pulmonary amyloidosis.
Tomas V. Gonzalez, MD, Anja C. Roden, MD, Brian J. Bartholmai, MD, Rebecca M. Lindell, MD   +3 more
doaj   +1 more source